Publications

A Practical Guide to Prescribing Sublingual Immunotherapy Tablets in North America for Pediatric Allergic Rhinoconjunctivitis

This clinical guide supports pediatric-focused implementation of SLIT tablets for allergic rhinitis. Dr. Rance’s contributions highlight patient selection, safety protocols, and adherence strategies. BioVision uses these principles to shape pediatric launch strategy, training platforms, and stakeholder engagement for novel immunotherapies.

Blaiss, M et al. Frontiers in Pediatrics, 2023

Degree of Fear of Needles and Preferred Allergy Immunotherapy Treatment Among Children with Allergic Rhinitis: Caregiver Survey Results

This study reveals the impact of needle fear on caregiver preferences for SLIT over SCIT in children. As an author, Dr. Rance brings forward data-driven insights into behavioral barriers and patient-centered treatment design. BioVision leverages this perspective to shape adherence programs, HCP communication, and product value narratives.

Rance et al. Frontiers in Pediatrics, 2024

Diagnosis and Management of Allergic Rhinoconjunctivitis in U.S. Children and Adolescents

This publication provides a comprehensive review of diagnostic challenges and care strategies for pediatric ARC. Dr. Rance helped craft practical pathways for clinicians and policy recommendations. At BioVision, this translates into clinical positioning strategy, cross-functional alignment, and advocacy integration for pediatric allergy portfolios.

Rance et al. Journal of Pediatric Health Care, 2024

Extrapolating Evidence-Based Medicine of AIT Into Clinical Practice in the United States

This globally recognized framework outlines the strategic use of allergen immunotherapy (AIT) across different patient groups, emphasizing early intervention, long-term disease management, and the importance of real-world application. The framework promotes a patient-centered approach to AIT that aligns with shared decision-making, clinical evidence, and practical use. It also underscores the need for collaboration among physicians, payers, and public health systems to improve access and adherence.

As an author, Dr. Rance contributed to the multidisciplinary vision for enhancing access and outcomes through system-level alignment. This work directly supports BioVision’s consulting focus on medical strategy, combining scientific rigor with practical tactics to help medical affairs teams support therapies—like AIT—that are highly effective, underutilized, and crucial for reducing disease burden.

Calderon et al. Journal of Allergy Clinical Immunology: In Practice, 2022

Randomized Trial of Pharmacokinetic and Pharmacodynamic Effects of 13.2 mg Intranasal Epinephrine Treatment in Congestion

This pivotal pharmacokinetic study evaluated whether nasal congestion affects the absorption of intranasal epinephrine—a critical question in life-threatening allergic reactions. The results demonstrated that epinephrine absorption was actually enhanced under congestion conditions and well tolerated.

Dr. Rance’s involvement supports BioVision Consulting’s leadership in advancing clinical solutions for anaphylaxis treatment and delivery innovation.

Dworaczyk et al. Annals of Allergy Asthma Immunology, 2024

Real-World Evidence of the Costs of Allergic Rhinitis and Allergy Immunotherapy in the Commercially Insured United States Population

This study presents compelling real-world evidence on the economic burden of allergic rhinitis and the cost-effectiveness of allergy immunotherapy (AIT) in the U.S. commercially insured population. The findings highlight that AIT significantly reduces overall healthcare utilization and costs compared to other treatments for allergic rhinitis.

As a co-author, Dr. Rance contributed to interpreting the data in the context of patient access and long-term management strategies, a core focus of BioVision Consulting’s mission to help translate data into optimized outcomes.

Tkacz et al. Current Medical Research and Opinion, 2021

Real-World Mapping of Allergy Immunotherapy in the United States: The Argument for Improving Adherence

This publication maps the landscape of allergy immunotherapy (AIT) in the U.S., revealing key geographic and demographic trends in patient access and clinical practice. The data-driven insights provide a framework for targeting underserved populations and improving adherence strategies.

Dr. Rance’s contribution emphasizes the actionable use of this real-world data to support payer conversations and practice-based change. BioVision integrates these findings into access strategy, messaging frameworks, and stakeholder engagement planning.

Stone et al. Allergy & Asthma Proceedings, 2021